Updated

Federal regulators and seven states have moved against pharmaceutical executive Martin Shkreli for alleged violations of prior consent orders, accusing him of continuing to manipulate biopharma stocks in violation of existing agreements. The action underscores ongoing regulatory scrutiny of Shkreli's activities in the biotech and pharmaceutical sector despite his prior legal troubles and criminal convictions.